FDA approved levacetylleucine (Aqneursa) for ataxia in ataxia-telangiectasia, the first therapy for the disease, in patients 15 kg or heavier.
|Articles|July 18, 2022
Achieving Full Collections: Why Revenue Cycle Management is Key to Practice Success
Advertisement
With everything going on in the economy, managing the nitty gritty of your practice is one of the last headaches a physician needs to deal with. Between staffing shortages and rising costs, practices need a leading-edge solution.
Revenue Cycle Management (RCM) eliminates variability from staff turnover, and in turn increases the accountability and reliability of your practice. Download this whitepaper to learn more about which unique RCM system is the right fit for your practice.
Fill out the form below to download the whitepaper:
Sponsored by:
Advertisement
Related to this article
Tallie Z. Baram, MD, talks about how adding a measure of childhood unpredictability to ACEs screening may help pediatricians identify children at risk for mental health problems.
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
The FDA granted priority review to efzimfotase alfa for HPP in patients aged 2 years and older; a decision is expected in the first half of 2027.
Adolescent VALIANT subgroup data show pegcetacoplan cut proteinuria 75% vs placebo, supporting its expanded pediatric kidney indication.
The FDA approved Fayuvi (rebisufligene etisparvovec-hopf), a one-time AAV9 gene therapy, as the first treatment for pediatric MPS IIIA (Sanfilippo syndrome type A).
Aquestive resubmitted its NDA for dibutepinephrine sublingual film Anaphylm, citing new human factors and PK data addressing the FDA's CRL.
Melissa Wallach, MD, FAAP, discusses what pediatricians should know about updated screening, supplementation, and treatment recommendations for iron deficiency.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Updated AAP guidance changes iron deficiency screening and treatment in children
2
Tezepelumab meets co-primary and secondary endpoints in phase 3 eosinophilic esophagitis trial
3
How Breast Milk Shapes Gut Microbiome Signaling and Immunity
4
FDA approves levacetylleucine as first treatment for ataxia in ataxia-telangiectasia
5